S250 The Journal of Heart and Lung Transplantation, Vol 37, No 4S, April 2018 outcome compared to mismatched gender transplants in 16 years of follow up (43% vs 31%, p=0.006). A gender mismatched female donor transplanted into a male showed a 5 year survival of 56%, whereas a gender matched transplant showed a 5 year survival of 75% (female-female) respectively 70% (male-male) (p=0.006). A male donor transplanted into a female showed a high peri-operative mortality that eventually led to a 5-year survival of 43%. Recipient age, donor age, CMV, EBV and smoking status of the donor did not significantly affect survival outcome. Conclusion: This significantly worse long-term survival outcome of female donors in gender mismatched lung transplant recipients and the extremely high peri-operative mortality in gender mismatched male donors needs fur- ther elucidation. ( 620) Multiple Listing Does Not Improve Outcomes in Lung Transplantation D. Joyce , 1 A. Szabo, 2 Z. Yin, 2 G. Haasler, 3 K. Presberg, 4 S. Dolan, 4 L.D. Joyce. 3 1 Medical College of Wisconsin, Milwaukee, WI; 2 Biostatistics, Medical College of Wisconsin, Milwaukee, WI; 3 Surgery, Medical College of Wisconsin, Milwaukee, WI; 4 Medicine, Medical College of Wisconsin, Milwaukee, WI. Purpose: The impact of multiple listing (ML) strategies on outcomes in lung transplantation is unknown. We hypothesized that the practice of mul- tiple listing would fail to demonstrate meaningful benefits to lung transplant candidates. Methods: A retrospective review of the UNOS registry for 23,508 patients who underwent lung transplantation between May 1, 2005 and March 31, 2017 was performed. A Cox regression model with a time-dependent second- listing indicator was performed to evaluate the effect of ML on transplanta- tion, while controlling for other risk factors. Cumulative incidence (CI) of receiving a transplant, wait list mortality, and post-transplant survival were compared between the single listing (SL) and ML cohorts. Results: A total of 548 patients were listed in more than one center (2.3%). Of these, 506 (92.3%) were listed in two centers, 39 (7.1%) were listed in three centers, and 3 (0.5%) were listed in four centers. The CI of receiving a transplant at two years was 0.74 (95% CI: 0.74-0.75) in the SL cohort and 0.77 (0.73-0.81) after the start of the second listing in the ML cohort. Adjusting for age, gender, and lung allocation score, initiation of a second listing increased the chance of receiving a transplant (HR=3, 95% CI 2.7-3.3, p<0.001). Transplantation occurred in the initial listing center in 103 patients (29.9%). Based on the Cox model for death, ML did not impact on wait list mortality (0.94 [0.58-1.51], p= 0.786). As shown in the figure, there was no significant difference between SL and ML with respect to survival at one year (single 0.86 [0.86-0.87], multiple 0.86 [0.82-0.90]) or three years (single 0.69 [0.68-0.70], multiple 0.73 [0.67-0.78]) after transplant. Conclusion: Although initiating a second listing was associated with a sub- stantial increase in the chance of receiving a transplant, there was no differ- ence in post-transplant or wait list mortality. Based on these findings, patients are unlikely to derive a meaningful outcome benefit from a ML strategy. Curve using variables, e.g. age, gender, ethnicity, BMI, length of stay (LOS), ECMO and inhaled NO usage, blood groups and types of procedures. Using SAS program, data were expressed as Mean ± standard deviation and p<0.05 was considered significant. Results: During 1987 to 2014, 143,323 various organs were transplanted, out of which 27,980 lungs transplanted patients were available to be sorted out. Out of these, redo-LTx were 1097 patients where 597 had double and 500 had single lungs redo-transplantation. Demographics showed 52% male, 87% white, 6% black, 5% Latino, and 2% others, recipient's median age 46, median BMI 22 kg/m 2 , median LOS 19 days, blood groups O-46%, A-40%, B-10%, AB-4%, ECMO-4% and inhaled NO-1% usage. Log-rank test for equality of survivor functions between redo DLT vs. SLT showed trend towards double lungs redo-LTx (Hz .84, 95% CI .71- 1.0; p=0.092), age (Hz .99, 95% CI .68-.99; p=0.68), blood group (Hz 1.0, 95% CI .54-.89; p=0.61), ethnicity (Hz .98, 95% CI 0.78 - 1.24; p=0.91), female gender (Hz 1.09, 95% CI .88 - 1.20; p=0.71). Kaplan-Meier graph showed redo LTx 70% survival at 1 year (95% CI .66-.73), 48% survival at 3 years (95% CI .43- .52), 37% survival at 5 years (95% CI .32-.42) with p=0.18 (DLT vs. SLT). Conclusion: Survival outcomes from redo LTx are lower than current lung transplantation survival. There was a trend towards better long-term survival in redo double lung transplantation although short- and medium-term sur- vival had no differences. Newer era data are needed to compare the previous older era data. ( 618) WITHDRAWN ( 619) Donor-recipient Gender-mismatches Correlate With Survival Outcome J.M. Kwakkel-van Erp , 1 H.G. Otten, 2 N.P. van der Kaaij, 3 S.A. Braithwaite, 4 E.D. Oudijk, 5 D.A. van Kessel, 5 J.C. Grutters, 5 B. Luijk, 1 E.A. van de Graaf. 1 1 Respiratory Medicine, Univ Med Ctr Utrecht, Utrecht, Netherlands; 2 Immunology, Univ Med Ctr Utrecht, Utrecht, Netherlands; 3 Cardio-Thoracic Surgery, Univ Med Ctr Utrecht, Utrecht, Netherlands; 4 Anesthesiology, Univ Med Ctr Utrecht, Utrecht, Netherlands; 5 Respiratory Medicine, St. Antonius Hospital, Nieuwegein, Netherlands. Purpose: In different allo-organ transplantations such as heart and kidney transplantation, feminine donor organs are associated with a significant decreased long-term survival outcome. The aim of our study was to deter- mine if gender mismatches influence survival outcomes in patients after lung transplantation. Methods: In this retrospective, single center study of 375 adult lung trans- plant recipients (median follow-up of 1417 days; range 1-5907), we analyzed long-term survival and the effect of gender mismatches between recipient and donor (Kaplan-Meier, multivariate regression). Results: Slighty more females (51.5%) were transplanted (median age 50 years; range 16-65) compared to men (median age 51 years; range 17-65; p=n.s.). Matched gender transplants showed a better long-term survival